New muscle-activating therapy could support healthier aging

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss.

The question of how to intervene pharmacologically in age-related metabolic decline without damaging the very tissues that preserve vitality has become a key challenge for longevity science. GLP-1 receptor agonists may be enjoying their moment in the sun, with headlines touting their capacity to drive weight loss and improve glycemic control – but concerns about their tendency to reduce lean mass have been increasingly voiced, particularly by those interested in aging well rather than simply growing thinner.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3519

Atrogi

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Atrogi is a clinical-stage biopharmaceutical company headquartered in Stockholm, Sweden, focused on developing first-in-class small-molecule therapeutics targeting metabolic disorders. The company's lead candidate, ATR-258, is a GRK-biased β2-adrenergic receptor agonist designed to promote fat loss while preserving muscle mass, addressing type 2 diabetes and obesity through a novel mechanism that mimics the metabolic effects of exercise. Atrogi's approach targets the underlying pathophysiology of metabolic disease by modulating GPCR signaling pathways, with a broader pipeline addressing muscle-wasting conditions and related metabolic complications.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE